HOMOGENEOUS PREPARATIONS OF IL-31

• US 20100297065A1
• Filed: 06/04/2009
• Published: 11/25/2010
• Est. Priority Date: 01/28/2005
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: BUKOWSKI, THOMAS R., BRADY, LOWELL J., CHAN, CHUNG-LEUNG
• Application Number:
  US12/478,185
• Publication Number:
  US 20100297065A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/54 Interleukins [IL]
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.

Claims

1. An isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

18.

2. An isolated polypeptide consisting of the amino acid sequence as shown in SEQ ID NO:

18.

3. A formulation comprising:

an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO;

18; and

a pharmaceutically acceptable vehicle.

4. A kit comprising the formulation of claim 3.